These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 32162368)

  • 1. Regulatory and health technology assessment advice on postlicensing and postlaunch evidence generation is a foundation for lifecycle data collection for medicines.
    Moseley J; Vamvakas S; Berntgen M; Cave A; Kurz X; Arlett P; Acha V; Bennett S; Cohet C; Corriol-Rohou S; Du Four E; Lamoril C; Langeneckert A; Koban M; Pasté M; Sandler S; Van Baelen K; Cangini A; García S; Obach M; Gimenez Garcia E; Varela Lema L; Jauhonen HM; Rannanheimo P; Morrison D; Van De Casteele M; Strömgren A; Viberg A; Makady A; Guilhaume C
    Br J Clin Pharmacol; 2020 Jun; 86(6):1034-1051. PubMed ID: 32162368
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postlaunch evidence generation practices among health technology assessment bodies in Europe.
    Puñal-Riobóo J; Varela-Lema L; Guilhaume C; Galbraith M; Bélorgey C; Faraldo MJ; Meillassoux A
    Int J Technol Assess Health Care; 2022 Apr; 38(1):e33. PubMed ID: 35437135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strengthening the Interface of Evidence-Based Decision Making Across European Regulators and Health Technology Assessment Bodies.
    Jansen E; Hines PA; Berntgen M; Brand A
    Value Health; 2022 Oct; 25(10):1726-1735. PubMed ID: 35370077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRUST4RD: tool for reducing uncertainties in the evidence generation for specialised treatments for rare diseases.
    Annemans L; Makady A
    Orphanet J Rare Dis; 2020 May; 15(1):127. PubMed ID: 32456653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrating health technology assessment requirements in the clinical development of medicines: the experience from NICE scientific advice.
    Maignen F; Osipenko L; Pinilla-Dominguez P; Crowe E
    Eur J Clin Pharmacol; 2017 Mar; 73(3):297-305. PubMed ID: 27942759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early dialogue with health technology assessment bodies: a European perspective.
    Cuche M; Beckerman R; Chowdhury CA; van Weelden MA
    Int J Technol Assess Health Care; 2014 Dec; 30(6):571-8. PubMed ID: 25816822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving the contribution of regulatory assessment reports to health technology assessments--a collaboration between the European Medicines Agency and the European network for Health Technology Assessment.
    Berntgen M; Gourvil A; Pavlovic M; Goettsch W; Eichler HG; Kristensen FB
    Value Health; 2014 Jul; 17(5):634-41. PubMed ID: 25128058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.
    Tafuri G; Pagnini M; Moseley J; Massari M; Petavy F; Behring A; Catalan A; Gajraj E; Hedberg N; Obach M; Osipenko L; Russo P; Van De Casteele M; Zebedin EM; Rasi G; Vamvakas S
    Br J Clin Pharmacol; 2016 Oct; 82(4):965-73. PubMed ID: 27245362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations.
    Tafuri G; Lucas I; Estevão S; Moseley J; d'Andon A; Bruehl H; Gajraj E; Garcia S; Hedberg N; Massari M; Molina A; Obach M; Osipenko L; Petavy F; Petschulies M; Pontes C; Russo P; Schiel A; Van de Casteele M; Zebedin-Brandl EM; Rasi G; Vamvakas S
    Br J Clin Pharmacol; 2018 May; 84(5):1013-1019. PubMed ID: 29370449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structured Benefit-Risk Assessment Across the Product Lifecycle: Practical Considerations.
    Smith MY; Benattia I; Strauss C; Bloss L; Jiang Q
    Ther Innov Regul Sci; 2017 Jul; 51(4):501-508. PubMed ID: 30227054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PASSCLAIM - Synthesis and review of existing processes.
    Richardson DP; Affertsholt T; Asp NG; Bruce A; Grossklaus R; Howlett J; Pannemans D; Ross R; Verhagen H; Viechtbauer V
    Eur J Nutr; 2003 Mar; 42 Suppl 1():I96-111. PubMed ID: 12664324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.
    Vreman RA; Naci H; Goettsch WG; Mantel-Teeuwisse AK; Schneeweiss SG; Leufkens HGM; Kesselheim AS
    Clin Pharmacol Ther; 2020 Aug; 108(2):350-357. PubMed ID: 32236959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postlaunch evidence-generation studies for medical devices in Spain: the RedETS approach to integrate real-world evidence into decision making.
    Serrano-Aguilar P; Gutierrez-Ibarluzea I; Díaz P; Imaz-Iglesia I; González-Enríquez J; Castro JL; Espallargues M; García-Armesto S; Arriola-Bolado P; Rivero-Santana A; Perestelo-Pérez L; González-Pacheco H; Álvarez-Pérez Y; Faraldo-Vallés MJ; Puñal-Riobóo J; Ramallo-Fariña Y; Sánchez-Gómez LM; Asua-Batarrita J; Reviriego-Rodrigo E; Moreno-Rodríguez A; Juárez-Rojo C; Vicente-Saiz M; Orejas-Pérez E; Knabe-Guerra J; Prieto-Yerro I; González Del Yerro-Valdés C
    Int J Technol Assess Health Care; 2021 May; 37(1):e63. PubMed ID: 33942712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA.
    Janssens R; Russo S; van Overbeeke E; Whichello C; Harding S; Kübler J; Juhaeri J; Bywall KS; Comanescu A; Hueber A; Englbrecht M; Nikolenko N; Pravettoni G; Simoens S; Stevens H; Hermann R; Levitan B; Cleemput I; de Bekker-Grob E; Veldwijk J; Huys I
    Patient; 2019 Oct; 12(5):513-526. PubMed ID: 31222436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.